Flagship Pioneering, investor in Moderna raises $3.4 billion funds

Flagship Pioneering, the bioplatform company, and the venture capital investor in Moderna, today announced that it had raised additional funding of $2.23 billion, which brings its total funds to $3.37 billion.

Flagship re-opened its Fund VII in April to current Limited Partners and a select group of new investors to support its next generation of human health and sustainability companies.

The pharmaceutical industry is attracting a lot of investment with many early-stage companies vying to make treatments and vaccines to tackle Covid-19.

Biotechnology Moderna Flagship Pioneering

Flagship Pioneering’s modus operandi was to provide a biotech platform for building technologies that could be used in a range of illnesses rather than focusing on research on one particular disease.

Noubar Afeyan, the founder of Flagship Pioneering, said: “The expanded capital base is going to allow us to . . . conduct pioneering science, company creation and growth all under one roof.” He added, “Biotechnology is at the leading edge of technological progress, challenging us to think beyond incremental advances and take big leaps – and Flagship Pioneering is focused on actively leaping to the scientific spaces ripe for disruption.”

The company plans to use the cash over the next three years. Flagship now has an aggregate capital pool of $6.7 billion, with $14.1 billion assets under management.

Stephen Berenson, Managing Partner, Flagship Pioneering, said Flagship plans to support first-in-category platform companies, spanning human therapeutics, agriculture, and nutrition. The company also plans to invest in Preemptive Medicine and Health Security Initiative.

The Massachusetts-based company believes in developing technologies and establishing companies in-house. Teams are built around one specific area of expertise, and then when some concrete research develops, the division is hived off to form independent companies.

“It’s not in the traditional sense of the word an investment fund . . . none of what we do comes from outside,” Afeyan, who founded Flagship in 2000, told the Financial Times. “It is dedicated to advance each and every bio platform that we invent in-house.”

Flagship established Moderna in 2010 with the aim of developing mRNA therapeutics. Moderna has sold $1.7bn worth of Covid jabs in the first three months of the year and its share price has rocketed more than 1,000 percent since the start of 2020. Afeyan said Flagship believes in “an unbounded attempt to create scientific advances coupled with product advances”. He said that developing vaccines at Moderna began by asking “if we could use a code molecule or some kind of a molecule that could instruct the body to make any drug we wanted”.

Afeyan said Flagship’s modus operandi was to provide a biotech platform for building technologies that could be used in a range of illnesses rather than focusing on research on one particular disease.

Moderna is currently carrying out phase 1 trials of its mRNA technology on HIV and flu. Afeyan said. “Underlying health conditions made this pandemic the devastation that it was because there were all these underlying health comorbidities that made it worse,” he said. “We think we’re going to see a world in the future where we’re going to be able to intervene before diseases manifest.”

Flagship has filed for more than 300 patent applications from Flagship Labs and its companies have 53 clinical programs and 150 pre-clinical programs currently underway.

Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Tesla expected to make a killing in Bitcoin profits in next earning report

Tesla expected to make a killing in Bitcoin profits in next earning report

The price of Bitcoins has rallied to another high in October after hitting around $64,800 in April. This time it has hit over $58,000 on Oct. 14.
12 hours ago
Tesla Cybertruck V/s Rivian’s R1T

Tesla Cybertruck V/s Rivian’s R1T

The Tesla Cyberturck left many disappointed with its alien space ship-like design; though both trucks are still under production, what matters most is what comes under the hood.
2 days ago
College sports is multibillion dollar industry in the US

College sports is multibillion dollar industry in the US

According to data analyzed by GOBankingRates, head football coaches, closely followed by basketball coaches, easily rack up seven-figure salaries in the US.
3 days ago
Top women influencers in finance and wealth management

Top women influencers in finance and wealth management

It is only in the last century or so that women have been publicly acknowledged for their roles as leaders in various fields. Here’s a list of women influencers by Industry Leade
4 days ago
Brian Goldner, who led Hasbro’s transformation into an entertainment giant, passes away at 58

Brian Goldner, who led Hasbro’s transformation into an entertainment giant, passes away at 58

Brian Goldner, the CEO and Chairman of toymaker Hasbro, has died at age 58, the company said Tuesday (Oct. 12).
6 days ago
JPMorgan Chase CEO Jamie Dimon slams Bitcoin as worthless

JPMorgan Chase CEO Jamie Dimon slams Bitcoin as worthless

JPMorgan Chase CEO Jamie Dimon took another potshot at Bitcoin on Monday by calling the cryptocurrency “worthless” likening trading BTC to smoking cigarettes.
7 days ago